Status:
COMPLETED
INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs
Lead Sponsor:
Incyte Corporation
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This was a randomized, double blind, placebo controlled, dose ranging, parallel group study. Participants who had active rheumatoid arthritis (RA) who had inadequate response to any disease modifying ...
Eligibility Criteria
Inclusion
- Must have rheumatoid arthritis which has been inadequately controlled with at least one DMARD
- For subjects receiving antimalarials, they must be treated with antimalarials for at least 6 months and receiving a stable daily dose
- For subjects receiving sulfasalazine, they must be treated with Sulfasalazine (SSZ) for at least 6 months and receiving a stable daily dose of no more than 3 grams per day
- For subjects on methotrexate, they must be treated with methotrexate for at least 6 months, and receiving a stable weekly dose of methotrexate between 7.5 and 25 mg
- For subjects on leflunomide, they must be treated with leflunomide for at least 6 months, and receiving a stable dose of leflunomide between 10 to 20 mg
- For subjects receiving corticosteroids, they must be on a dose not to exceed 10 mg of prednisone daily
- Active rheumatoid arthritis at the time of screening defined by the following: 6 or more joints tender or painful on motion and 4 or more swollen joints and at least one of the following two: Erythrocyte sedimentation rate (ESR) greater than or equal to 28 mm/hr or C-reactive protein (CRP) greater than or equal to 7 mg/liter
- Have evidence of lack of risk for tuberculosis
Exclusion
- Current or recent viral, bacterial, fungal, parasitic or mycobacterial infection requiring systemic therapy
- History of infected joint prosthesis
- Subjects who have a current or recent history of severe, progressive, uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological or cerebral disease
- Subjects who have received treatment with the following drugs or drug classes within the specified timeframe: prior treatment with rituximab within 12 months, prior treatment with an oral Janus kinase (JAK) inhibitor, DMARDs or other anti-rheumatic therapies not specified and allowed according to protocol, treatment with any investigational medication within 12 weeks or 5 half-lives (whichever is longer), and treatment with a biologic agent within 12 weeks prior to the first dose of study medication
- Subjects with a past history of neutropenia, thrombocytopenia or anemia requiring transfusion other than at the time of trauma or surgery, and subjects that meet protocol specified laboratory measures
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
127 Patients enrolled
Trial Details
Trial ID
NCT00902486
Start Date
May 1 2009
End Date
July 1 2010
Last Update
September 4 2018
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Paradise Valley, Arizona, United States
3
Peoria, Arizona, United States
4
Phoenix, Arizona, United States